S. 27, The Preserve Access to Affordable Generics Act (4 wiki edits: view article ↓)

  • This item is from the 112th Congress (2011-2012) and is no longer current. Comments, voting, and wiki editing have been disabled, and the cost/savings estimate has been frozen.
  • This bill, or a similar bill, was reintroduced in the current Congress as S. 214, The Preserve Access to Affordable Generics Act.

S. 27 would prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market.

(

Learn More

    Saves: $29.35 per
    and decreases their $162,301.27 share of the national debt by $41.68.
    (source info)

  • Read the Bill
  • Read an Analysis of the Bill

To What Comittee was this Bill Referred?

From the Blog

WashingtonWatch.com Digest – November 14, 2011

This is the WashingtonWatch.com email newsletter for the week of November 14, 2011. Subscribe (free!) here. email newsletter | tell a friend | wiki | about | home | log in On the Blog: A Budget Amendment, But No Budget Congress plans to take up a balan...

Visitor Comments Comments Feed for This Bill

There are currently no comments for this bill

RSS Feeds for This Bill

Keep yourself updated on user contributions and debates about this bill! (Learn more about RSS.)